EFSEVIA ALBANIS, MD
Osteopathic Medicine in New York, NY
License number
New York 202211
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
5 Street Box 1118 Mt, New York, NY 10029
Phone
(212) 241-0034
(212) 289-7738 (Fax)
(212) 987-3100
(212) 731-5210 (Fax)
(212) 289-7738 (Fax)
(212) 987-3100
(212) 731-5210 (Fax)
Personal information
See more information about EFSEVIA ALBANIS at radaris.comName
Address
Phone
176 E 77Th St APT 14E, New York, NY 10075
New York, NY
205 95Th St, New York, NY 10128
205 95Th St, New York, NY 10128
Organization information
See more information about EFSEVIA ALBANIS at bizstanding.comEfsevia Albanis MD
5 E 98 St, New York, NY 10029
Industry:
Internist
Phone:
(212) 241-0034 (Phone)
Efsevia Albanis
Professional information
Dr. Efsevia Albanis, New York NY - MD (Doctor of Medicine)
Specialties:
Gastroenterology
Address:
205 E 95Th St, New York 10128
1425 Madison Ave SUITE 1123, New York 10029
(212) 659-9508 (Phone), (212) 849-2574 (Fax)
1425 Madison Ave SUITE 1123, New York 10029
(212) 659-9508 (Phone), (212) 849-2574 (Fax)
Certifications:
Gastroenterology, 2000, Internal Medicine, 1997
Awards:
Healthgrades Honor Roll
Languages:
English, Greek
Education:
Medical School
Mount Sinai School of Medicine
Graduated: 1994
Mount Sinai Hospital
St Luke's Roosevelt Hosp
Mount Sinai School of Medicine
Graduated: 1994
Mount Sinai Hospital
St Luke's Roosevelt Hosp
Efsevia Albanis, New York NY
Specialties:
Gastroenterologist
Address:
5 E 98Th St, New York, NY 10029
Education:
Mount Sinai School of Medicine - Doctor of Medicine
Mount Sinai Hospital, The - Fellowship - Hepatology
Mount Sinai Hospital, The - Fellowship - Hepatology
Treatment Of Hepatic Fibrosis With Imatinib Mesylate
US Patent:
2005014, Jun 30, 2005
Filed:
Dec 2, 2004
Appl. No.:
11/002715
Inventors:
Scott Friedman - Scarsdale NY, US
Efsevia Albanis - New York NY, US
Efsevia Albanis - New York NY, US
Assignee:
Mount Sinai School of Medicine of New York University - New York NY
International Classification:
A61K031/506
US Classification:
514252180
Abstract:
Disclosed herein is a method for treating hepatic fibrosis comprising administering to a patient in need of such treatment an amount effective to treat hepatic fibrosis of imatinib mesylate. This is based on the ability of imatinib mesylate to down regulate stellate cell activation in culture and in vivo. Hepatic fibrosis is not limited to patients with chronic Hepatitis B, Hepatitis C, non-alcoholic steatophepatitis (NASH), alcoholic liver disease, metabolic liver diseases (Wilson's disease, hemochromatosis), biliary obstruction (congenital or acquired) or liver diseases associated with fibrosis of unknown cause.